Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Indivior Pharmaceuticals (INDV) Other Gross PP&E Adjustments (2022 - 2026)

Indivior Pharmaceuticals has reported Other Gross PP&E Adjustments over the past 5 years, most recently at $246.0 million for Q1 2026.

  • For Q1 2026, Other Gross PP&E Adjustments rose 53.75% year-over-year to $246.0 million; the TTM value through Mar 2026 reached $246.0 million, up 53.75%, while the annual FY2025 figure was $219.0 million, 52.08% up from the prior year.
  • Other Gross PP&E Adjustments for Q1 2026 was $246.0 million at Indivior Pharmaceuticals, up from $219.0 million in the prior quarter.
  • Over five years, Other Gross PP&E Adjustments peaked at $246.0 million in Q1 2026 and troughed at -$39.0 million in Q3 2024.
  • A 5-year average of $81.5 million and a median of $119.0 million in 2023 define the central range for Other Gross PP&E Adjustments.
  • Biggest five-year swings in Other Gross PP&E Adjustments: fell 21.88% in 2024 and later soared 614.71% in 2025.
  • Year by year, Other Gross PP&E Adjustments stood at -$31.0 million in 2022, then skyrocketed by 483.87% to $119.0 million in 2023, then rose by 21.01% to $144.0 million in 2024, then skyrocketed by 52.08% to $219.0 million in 2025, then increased by 12.33% to $246.0 million in 2026.
  • Business Quant data shows Other Gross PP&E Adjustments for INDV at $246.0 million in Q1 2026, $219.0 million in Q4 2025, and $200.0 million in Q3 2025.